A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Trial Details

NCT ID

NCT07559474

Phase

PHASE1

Sponsor

Incyte Corporation

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• INCB123667

Locations (sample)

• Chandler, Arizona, United States|33.30616,-111.84125
• Orlando, Florida, United States|28.53834,-81.37924
• San Antonio, Texas, United States|29.42412,-98.49363
• San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

• Ability to comprehend and willingness to sign a written ICF for the study.
• Aged 18 to 80 years, inclusive, at the time of signing the ICF.
• Moderate or severe hepatic impairment based on CP score.
• Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 1…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.